Form 10-Q/A
NATERA, INC. filed this Form 10-Q/A on 02/06/2019
Document Outline
Entire Document (514.8 KB)
Subdocument 1 - 10-Q/A - 10-Q/A
Page 1 - UNITED STATES
Page 2 - EXPLANATORY NOTE
Page 3 - ITEM 6 EXHIBITS
Page 4 - N/A
Page 5 - SIGNATURES
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - 1.4 [*] Technical Performance Standard means the Product having been validated to meet, and then con
Page 3 - 1.12 Exclusivity Performance Standards means QIAGEN achieving the following: (a) submitting a [*] fo
Page 4 - 1.21 IVD or In Vitro Diagnostic means a medical device, whether used alone or in combination, intend
Page 5 - Combination Product, and such other products and services bundled with the Product collectively, Bun
Page 6 - 1.32 Party or Parties means each of QIAGEN and Natera individually or collectively.
Page 7 - 1.40 Software means, to the extent owned, used, controlled, marketed, designed, sold, licensed by, s
Page 8 - 2.2.2 Permitted Sublicenses. The Technology License granted to QIAGEN includes the right to sublicen
Page 9 - 2.7.2 Other Countries. The Parties shall in good faith discuss the possibility and their interest in
Page 10 - 3.1.5 Natera may end the Exclusive License Period by providing written notice to QIAGEN thereof at a
Page 11 - 4.2 [*] IVD Steering Committee. The Parties shall appoint designated representatives to form a joint
Page 12 - 4.4 Natera [*] of Sequencing System. To support development, registration, launch and market adoptio
Page 13 - 5.1.2 Natera shall provide reasonably necessary regulatory and quality assurance support, including
Page 14 - 5.6 Governmental Authority Inspections. Each Party shall promptly notify the other Party of any prop
Page 15 - 6. COMMERCIALIZATION
Page 16 - 6.4 Product Branding.
Page 17 - 6.5.3 Subject to QIAGEN satisfying QIAGEN s Supply Obligations, Natera shall fund and conduct a [*]
Page 18 - 6.7.2 Each Party shall hold in confidence all Personal Information obtained in the course of the dis
Page 19 - 6.12 Commercialization Commitment. QIAGEN commits to generating a minimum Net Sales of [*] during th
Page 20 - 7.2.2 provide prepayment of future royalties due to Natera of [*] ( Prepaid Royalties ) paid, as fol
Page 21 - 7.3.3 Remittance. Within thirty (30) calendar days after the end of each calendar quarter, commencin
Page 22 - 7.7.2 In the event that the Natera Auditor concludes that any additional payments are required for t
Page 23 - 7.8.2 In the event that the QIAGEN Auditor concludes that overpayments were made by QIAGEN for the p
Page 24 - 8.4 Debarment. Each Party represents, warrants and covenants that it has not, nor to its knowledge h
Page 25 - 8.6 Disclaimer.
Page 26 - 10. INTELLECTUAL PROPERTY
Page 27 - 10.4 Natera Assistance. Natera shall, upon QIAGEN s request, execute such documents, including any a
Page 28 - 10.9 Natera Noninterference. Natera shall not: (i) take any action that may interfere with any of QI
Page 29 - 11.4 Equitable Relief. The Parties understand and agree that this Article 11 is reasonable and neces
Page 30 - 12.2 IP Indemnification by QIAGEN. QIAGEN (i) will, at its sole expense, defend any Third Party Clai
Page 31 - 12.4 Infringement of a Third Party s Intellectual Property
Page 32 - 13. GENERAL INDEMNIFICATION
Page 33 - 13.4 Survival. The general indemnification obligations and assumptions of liabilities and obligation
Page 34 - 14.5.2 In the event Natera terminates this Agreement as a whole pursuant to Section 14.3 or 14.4, (a
Page 35 - 14.5.5 In the event QIAGEN terminates this Agreement as a whole pursuant to Section 14.3: (a) QIAGEN
Page 36 - 15.2 Entire Agreement. This Agreement, including any attachments, exhibits or schedules hereto or de
Page 37 - 15.7 Independent Contractors. The Parties hereto are independent contractors and nothing in this Agr
Page 38 - 15.9 SEC Filings. To the extent a Party believes in its reasonable judgment and pursuant to advice f
Page 39 - 15.14 Notices. Any notices and other communications provided for in this Agreement to be made by eit
Page 40 - N/A
Page 41 - EXHIBIT A
Page 42 - EXHIBIT B
Page 43 - EXHIBIT C
Page 44 - EXHIBIT D
Page 45 - EXHIBIT E
Page 46 - EXHIBIT F
Page 47 - N/A
Page 48 - EXHIBIT G
Page 49 - EXHIBIT H
Page 50 - EXHIBIT I
Page 51 - EXHIBIT J
Page 52 - EXHIBIT K
Subdocument 3 - EX-31.3 - EX-31.3
Page 1 - N/A
Subdocument 4 - EX-31.4 - EX-31.4
Page 1 - N/A
Shareholder Tools